Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.

N,N'-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB(2) inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A-C and the core structure in further SAR studies. Five compounds were developed and also confirmed as CB(2) inverse agonists with the highest CB(2) binding affinity (CB(2)K(i) of 22-85 nM, EC(50) of 4-28 nM) and best selectivity (CB(1)/CB(2) of 235- to 909-fold). Furthermore, osteoclastogenesis bioassay indicated that PAM compounds showed great inhibition of osteoclast formation. Especially, compound 26 showed 72% inhibition activity even at the low concentration of 0.1 μM. The cytotoxicity assay suggested that the inhibition of PAM compounds on osteoclastogenesis did not result from its cytotoxicity. Therefore, these PAM derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.

[1]  K. Altmann,et al.  Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. , 2011, Chemistry & biology.

[2]  B. Thiers.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2008 .

[3]  M. L. de Ceballos,et al.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. , 2001, Cancer research.

[4]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[5]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[6]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[7]  A. Makriyannis,et al.  The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940 (*) , 1996, The Journal of Biological Chemistry.

[8]  J. Huffman.  Cannabimimetic indoles, pyrroles and indenes. , 1999, Current medicinal chemistry.

[9]  Xiang-Qun Xie,et al.  Data Mining a Small Molecule Drug Screening Representative Subset from NIH PubChem , 2008, J. Chem. Inf. Model..

[10]  D. Piomelli,et al.  Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.

[11]  Xiang-Qun Xie,et al.  Data Mining a Small Molecule Drug Screening Representative Subset from NIH PubChem , 2008, J. Chem. Inf. Model..

[12]  S. Ralston,et al.  Cannabinoids and Bone: Friend or Foe? , 2010, Calcified Tissue International.

[13]  Xiang-Qun Xie,et al.  Recent Advances in Fragment-Based QSAR and Multi-Dimensional QSAR Methods , 2010, International journal of molecular sciences.

[14]  Qian Liu,et al.  3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. , 2006, Journal of medicinal chemistry.

[15]  G. Thakur,et al.  Cannabinergic ligands. , 2002, Chemistry and physics of lipids.

[16]  John W Huffman,et al.  Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. , 2008, Current topics in medicinal chemistry.

[17]  Yunfeng Chai,et al.  N,N′‐(Phenylmethylene)diacetamide Analogues as Economical and Efficient Ligands in Copper‐Catalyzed Arylation of Aromatic Nitrogen‐Containing Heterocycles. , 2009 .

[18]  I. Chessell,et al.  Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. , 2007 .

[19]  S. Friedman,et al.  Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[20]  Xiang-Qun Xie,et al.  3D structural model of the G‐protein‐coupled cannabinoid CB2 receptor , 2003, Proteins.

[21]  M. Maier,et al.  Synthesis of enamides from aldehydes and amides , 2004 .

[22]  Xiang-Qun Xie,et al.  Beta-caryophyllene is a dietary cannabinoid , 2008, Proceedings of the National Academy of Sciences.

[23]  Z. Xi,et al.  Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice , 2011, Nature Neuroscience.

[24]  Jay S. Fine,et al.  A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[25]  E. Schwarz,et al.  The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis , 2007, Annals of the rheumatic diseases.

[26]  G. Roodman,et al.  SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. , 2007, Blood.

[27]  Haizhen Zhong and J. Phillip Bowen.  GALAHAD Tripos, Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319. www.tripos.com. Contact company for pricing information. , 2007 .

[28]  R. Pertwee,et al.  Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.

[29]  P. Dubový,et al.  Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review , 2008, Pharmacology Biochemistry and Behavior.

[30]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[31]  K. Rice,et al.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.

[32]  A. Hohmann.  Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. , 2002, Chemistry and physics of lipids.

[33]  A. Hohmann,et al.  The endocannabinoid system and cancer: therapeutic implication , 2011, British journal of pharmacology.

[34]  Xiang-Qun Xie,et al.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. , 2012, Future medicinal chemistry.

[35]  H. Iwamura,et al.  In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[36]  P Ferrara,et al.  Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.

[37]  J. Gertsch,et al.  Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? , 2009, The Journal of pharmacy and pharmacology.

[38]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[39]  A. Poso,et al.  Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands , 2008, British journal of pharmacology.

[40]  I. Chessell,et al.  Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. , 2007, Journal of medicinal chemistry.

[41]  T. Nevalainen,et al.  Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. , 2005, Current medicinal chemistry.

[42]  N. Davoust,et al.  The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. , 2008, The Journal of biological chemistry.

[43]  M. Camilleri,et al.  Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects , 2008, Gut.

[44]  Herbert H Seltzman,et al.  Synthesis and Structure−Activity Relationships of Amide and Hydrazide Analogues of the Cannabinoid CB1 Receptor Antagonist N-(Piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) , 2002 .

[45]  Xiang-Qun Xie,et al.  Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. , 2011, International immunopharmacology.

[46]  G. Velasco,et al.  Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.

[47]  Sharangdhar S. Phatak,et al.  6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. , 2009, Journal of medicinal chemistry.

[48]  Jane C. Johnson,et al.  Role of Osteopathic Manipulative Treatment in Altering Pain Biomarkers: A Pilot Study , 2007, The Journal of the American Osteopathic Association.

[49]  C. Hassig,et al.  KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling , 2008, Molecular Cancer Therapeutics.